Somai Pharmaceuticals has partnered with Pacific Cannovation Company Limited to transform Thailand into a global hub for high-quality medicinal cannabis.
With Thailand emerging as Asia's fastest-growing medicinal cannabis market, projected to reach $1 billion in internal sales in 2024, the partnership hopes to elevate Thai cannabis to global prominence.
The agreement includes the distribution of medicinal cannabis flowers, extracts, and plans for future product development and clinical trials. Leveraging Somai's QA, regulatory, and inventory capabilities, this partnership ensures that patients worldwide receive only the highest quality products. Somai will sponsor PACCAN's state-of-the-art facilities to receive EU-GMP certification, enabling a seamless partnership leveraging each other's strengths.
"Our partnership is about setting a new global standard of partnerships where two cross-continent unique companies share and leverage each other to benefit a strong partnership of like-minded cultures of excellence," said Michael Sassano, CEO of Somai Pharmaceuticals. "Together with PACCAN, we're demonstrating that Thai medicinal cannabis can rival the best in the world, offering unparalleled quality, and European products can be successful in Asia. This partnership is not just about business, it's about collaboration, shared vision, and delivering the best outcomes for patients around the world."
For more information:
Somai Pharmaceuticals
www.somaipharma.eu